Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A phase I trial
Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A phase I trial
复制标题
DOI：
10.1016/s0360-3016(02)02902-4
复制
发表时间：
2002-09-01
影响因子：
7
通讯作者：
Rich, T
中科院分区：
文献类型：
--
作者：
Safran, H;Dipetrillo, T;Rich, T
目的：确定吉西他滨、紫杉醇和同步放射治疗胰腺癌的最大耐受剂量(MTD)和剂量限制毒性。方法和材料：20例局部不能切除的胰腺癌患者。初始剂量为吉西他滨75 mg/m(2)，紫杉醇40 mg/m(2)，每周1次，疗程6周。照射剂量为50.4Gy1.8Gy次。结果：3例患者中有3例在第二剂量(150 mg/m(2)/周)时出现腹泻、脱水、恶心、食欲减退等剂量限制毒性反应。吉西他滨中剂量为110 mg/m(2)/周，但出现胃肠道毒性和肺部肺炎。其MTD为京尼他滨75 mg/m(2)/周，紫杉醇40 mg/m(2)/周，同时放疗。在MTD接受治疗的11名患者中，有两名具有314级毒性。在MTD治疗的10例可评估患者中，4例有效(40%)，包括1例病理完全缓解。结论：吉西他滨的最大耐受量为75 mg/m(2)/周，紫杉醇40 mg/m~2/周，常规50.4Gy场。第二阶段放射治疗肿瘤学小组研究正在进行中。(C)2002年爱思唯尔科学公司。
Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of gemcitabine, paclitaxel, and concurrent radiation for pancreatic cancer.Methods and Materials: Twenty patients with locally unresectable pancreatic cancer were studied. The initial dose level was gemcitabine 75 mg/m(2) and paclitaxel 40 mg/m(2) weekly for 6 weeks. Concurrent radiation to 50.4 Gy was delivered in 1.8 Gy fractions. The radiation fields included the primary tumor, plus the regional peripancreatic, celiac, and porta hepatis lymph nodes.Results: Dose-limiting toxicities of diarrhea, dehydration, nausea, and anorexia occurred in 3 of 3 patients at the second dose level of genicitabine, 150 mg/m(2)/week. An intermediate dose level of gemcitabine, 110 mg/m(2)/week, was added, but gastrointestinal toxicity and pulmonary pneumonitis were encountered. The MTD therefore was genicitabine 75 mg/m(2)/week with paclitaxel 40 mg/m(2)/week and concurrent radiation. Two of 11 patients treated at the MTD had Grade 314 toxicity. Four of 10 assessable patients treated at the MTD responded (40%), including one pathologic complete response.Conclusion: The maximum tolerated dosage of gemcitabine is 75 mg/m(2)/week with paclitaxel 40 mg/m2/week and conventional 50.4 Gy radiation fields. A Phase II Radiation Therapy Oncology Group study is under way. (C) 2002 Elsevier Science Inc.